The vaccine is expected to be a breakthrough in the treatment of urinary tract infections.
REPUBLIKA.CO.ID, JAKARTA — Researchers at the University of Texas have studied the use of a whole-cell vaccine to treat urinary tract infections (UTIs). Cause bacteria ISK is known to have developed resistance to various antibiotics, so the vaccine is expected to be a new breakthrough in treatment.
This study has been published in American Chemical Society ACS Nano Journal. Assistant professor of biological sciences Dr Nicole De Nisco and professor of chemistry and biochemistry Dr Jeremiah Gassensmith, recently demonstrated the use of metal-organic frameworks (MOFs) to inactivate all bacterial cells and create a depot that allows the vaccine to last longer in the body.
This study has been tested on mice, and is proven to produce stronger antibodies and the survival rate is also much higher than the method vaccine preparation standard whole cells.
The American Urological Association estimates that 150 million cases of UTI occur every year worldwide. If not treated successfully, a UTI can lead to sepsis which can be fatal. Especially if you experience re-infection which generally occurs in postmenopausal women, although UTIs should still be watched out for by all women.
“Any reinfection is more difficult to treat. Even if you clear the bacteria from the bladder, the population persists elsewhere and usually becomes increasingly resistant to antibiotics,” De Nisco added. Times Now News, Tuesday (11/23).
These vaccines work by introducing small amounts of killed or weakened disease-causing germs, or some of their components, into the body. These antigens prompt the immune system to produce antibodies against certain diseases.
– .
